The CWRU professor studied 1 million Americans with type 2 diabetes, and stresses the result is an association, not proof semaglutide prevents Alzheimer's.
Recap by typeshit. Full story at Case Western Reserve University.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A mid-stage trial found adding Rezera's experimental drug ruvonoflast strengthened the anti-inflammatory effect of semaglutide, AllSci reports.
Lilly closed at $1,169.60, and one investor narrative puts fair value near $1,477, citing retatrutide's Phase 3 results against pricing pressure.
Loading…